Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

Recruiting

Phase 1

ARQ-154 FoamMaximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

Sponsor:

Arcutis Biotherapeutics, Inc.

Code:

NCT07340216

Conditions

Psoriasis

Eligibility Criteria

Sex: All

Age: 2 - 12

Healthy Volunteers: Not accepted

Interventions

ARQ-154 Foam 0.3%

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-18. This information was provided to ClinicalTrials.gov by Arcutis Biotherapeutics, Inc. on 2026-01-14.